Evidence From Humans
 
Print this page
No association of the 5' promoter region polymorphism of CYP17 with breast cancer risk in Japan
Hamajima, N., Iwata, H., Obata, Y., Matsuo, K., Mizutani, M., Iwase, T., Miura, S., Okuma, K., Ohashi, K., Tajima, K. Japanese Journal of Cancer Research. 2000. 91:9, 880-5.
Topic area
Body size - Genetic variability
Study design
Hospital based case-control study
Funding agency
Ministry of Education, Science, Sports, and Cultur
Study Participants
Menopausal Status
The menopausal status of women included in this study is listed here.
Pre menopausal
Post menopausal
Participant selection: Inclusion and exclusion criteria
Criteria used to select participants in the study.
Histopathologically confirmed prevalent cases, diagnosed less than 4 years prior to study date. Controls were noncancer outpatients at same hospital for annual health check up or during same period.
Exposures investigated
BMI, CYP17 allele frequencies, used PCR-RFLP
How exposure was measured
Biological Questionnaire, self-administered
Ethnic groups with separate analysis
If this study provided a separate analysis by ethnic or racial group, the groups are listed here.
No
Confounders considered
Other breast cancer risk factors, such as family history, age at first birth, and hormone replacement therapy use, that were taken into account in the study.
Yes: Models adjusted for age only
Genetic characterization included
If the study analyzed relationships between environmental factors and inherited genetic variations, this field will be marked “Yes.” “No”, if not.
Yes
Description of major analysis
Logistic regression analysis of CYP17 genotype and breast cancer, including effect modification by BMI
Strength of associations reported
In full group, age adjusted OR=0.97 (CI: 0.58-1.64) for heterozygote and OR=0.81 (CI: 0.39-1.68) for mutant homozygote
For BMI<22, OR=1.01 (CI: 0.49-2.09) in heterozygotes and OR=0.68 (CI: 0.24-1.90) for mutant homozygotes
For BMI >=22, OR=0.96 (CI: 0.45-2.07) for heterozygotes and OR=1.09 (CI: 0.38-3.13) for mutant homozygotes
Privacy notice   |   Copyright statement